Rosetta Genomics licenses Rockefeller University’s microRNA genes

The agreement encompasses viral and human microRNAs that will be added to Rosetta Genomics’s existing intellectual property estate, which includes two issued patents, two allowed patent applications, and 60 pending patent applications.

Rosetta Genomics has previously licensed Rockefeller University’s proprietary microRNAs for therapeutic and diagnostic uses, and this recent agreement allows the company access to a full range of potential microRNA applications based on these microRNAs.

Amir Avniel, president and CEO of Rosetta, said: “Our strategy continues to focus on supplementing our in-house IP portfolio with licensing agreements with key academic centers such as Rockefeller University.”